AU2006269462A1 - Methods of treating epileptogenesis - Google Patents

Methods of treating epileptogenesis Download PDF

Info

Publication number
AU2006269462A1
AU2006269462A1 AU2006269462A AU2006269462A AU2006269462A1 AU 2006269462 A1 AU2006269462 A1 AU 2006269462A1 AU 2006269462 A AU2006269462 A AU 2006269462A AU 2006269462 A AU2006269462 A AU 2006269462A AU 2006269462 A1 AU2006269462 A1 AU 2006269462A1
Authority
AU
Australia
Prior art keywords
formula
group
seizure
epilepsy
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006269462A
Other languages
English (en)
Inventor
Roy E. Twyman
Boyu Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37637731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006269462(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2006269462A1 publication Critical patent/AU2006269462A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2006269462A 2005-07-12 2006-07-07 Methods of treating epileptogenesis Abandoned AU2006269462A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69862505P 2005-07-12 2005-07-12
US60/698,625 2005-07-12
PCT/US2006/026277 WO2007008551A2 (en) 2005-07-12 2006-07-07 Use of 2-phenyl-l, 2-ethanedi0l-(di) carbamates for treating epileptogenesis and epilepsy

Publications (1)

Publication Number Publication Date
AU2006269462A1 true AU2006269462A1 (en) 2007-01-18

Family

ID=37637731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006269462A Abandoned AU2006269462A1 (en) 2005-07-12 2006-07-07 Methods of treating epileptogenesis

Country Status (16)

Country Link
US (1) US20070021501A1 (https=)
EP (1) EP1906946A2 (https=)
JP (1) JP2009501223A (https=)
KR (1) KR20080028485A (https=)
CN (1) CN101309680A (https=)
AR (1) AR054550A1 (https=)
AU (1) AU2006269462A1 (https=)
BR (1) BRPI0613010A2 (https=)
CA (1) CA2615127A1 (https=)
EA (1) EA200800295A1 (https=)
EC (1) ECSP088172A (https=)
IL (1) IL188728A0 (https=)
NO (1) NO20080739L (https=)
TW (1) TW200744575A (https=)
WO (1) WO2007008551A2 (https=)
ZA (1) ZA200801402B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
EP2968210B1 (en) * 2013-03-12 2024-09-11 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
KR102481631B1 (ko) * 2015-08-24 2022-12-27 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
ES3059582T3 (en) * 2016-02-29 2026-03-23 Bio Pharm Solutions Co Ltd Sulfamate derivative compounds, processes for preparing them and their uses
US20190022166A1 (en) * 2017-07-18 2019-01-24 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
CN115501344A (zh) * 2022-09-29 2022-12-23 重庆医科大学 一种铁螯合剂的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU3304997A (en) * 1996-05-31 1998-01-05 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
CA2360258A1 (en) * 1999-02-09 2000-08-17 Timothy L. Macdonald Felbamate derived compounds
MXPA03007717A (es) * 2001-02-27 2005-11-08 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
PL364640A1 (en) * 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder

Also Published As

Publication number Publication date
CA2615127A1 (en) 2007-01-18
WO2007008551A3 (en) 2008-06-19
KR20080028485A (ko) 2008-03-31
BRPI0613010A2 (pt) 2010-12-14
NO20080739L (no) 2008-04-10
TW200744575A (en) 2007-12-16
ZA200801402B (en) 2009-10-28
EP1906946A2 (en) 2008-04-09
IL188728A0 (en) 2008-11-03
EA200800295A1 (ru) 2008-12-30
CN101309680A (zh) 2008-11-19
US20070021501A1 (en) 2007-01-25
JP2009501223A (ja) 2009-01-15
AR054550A1 (es) 2007-06-27
ECSP088172A (es) 2008-03-26
WO2007008551A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
US20110152362A1 (en) Methods of treating epileptogenesis and epilepsy
US20090137652A1 (en) Methods for neuroprotection
US20070021501A1 (en) Methods of treating epileptogenesis
CA2587481A1 (en) Phenylalkylamino carbamates adjunctive therapy for depression
WO2007095608A2 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of disease modification of epileptogenesis
WO2006044472A1 (en) Carbamate compounds for use in treating neurodegenerative disorders
KR20090085071A (ko) 달팽이관 및 전정기관 장애의 치료 방법
EP1809273B1 (en) Use of 2-phenyl-1,2-ethanediol-(di)carbamates for treating epileptogenesis
MX2008000694A (en) Use of 2-phenyl-l, 2-ethanedi0l-(di) carbamates for treating epileptogenesis and epilepsy
HK1105583B (en) Use of 2-phenyl-1, 2-ethanediol-(di) carbamates for treating epileptogenesis

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application